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The misuse of designer benzodiazepines, as an alternative to prescription 
benzodiazepines and for drug-facilitated sexual assaults, has emerged as a growing threat, due in 
part to the ease of purchasing these drugs on the internet at low prices. Causing concern for 
safety, is the lack of dosage information resulting in users self-medicating, often leading to 
unintended overdoses, coma, or death at higher doses. With limited published data regarding 
quantification of designer benzodiazepines in forensic cases, a method was validated for the 
determination of thirteen and screening for two designer benzodiazepines in blood, in addition to 
a limited number of common designer benzodiazepines in the inhouse method. The developed 
method analyzed 3-hydroxyphenazepam, 4-chlorodiazepam, clobazam, clonazolam, 
delorazepam, deschloroetizolam, diclazepam, flualprazolam, flubromazepam, flubromazolam, 
flunitrazolam, meclonazepam, nifoxipam, pyrazolam, and zolazepam in 0.5 mL blood using 
liquid chromatography-tandem mass spectrometry. The analytes were treated with solid phase 
extraction before undergoing separation on a 𝐶18 column and analyzed on the mass spectrometer 
in electrospray positive mode using multiple-reaction monitoring. The linear range of the 
calibration curve was 1-200 ng/mL, and up to 500 ng/mL for 3-hydroxyphenazepam, clobazam, 
flubromazepam, and pyrazolam. 4-chlorodiazepam and zolazepam were tested for qualitative 
analysis only. The limits of detection and quantitation were 0.5 ng/mL (S/N>3) and 1 ng/mL, 
respectively. Other parameters tested included bias, precision, matrix effect, recovery, carryover, 
stability, interference, and dilution integrity which all yielded acceptable results. With the 
application of this method to blood specimens from the NYC Office of Chief Medical Examiner, 
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Benzodiazepines are drugs that are usually prescribed to treat various kinds of medical 
conditions including but not limited to anxiety, seizures, insomnia, and depression. However, 
benzodiazepines also come with several side effects, such as confusion, memory loss, loss of 
orientation, headaches, and have the potential of being addictive (Ogbru, 2018). Due to their 
psychoactive effects and side effects, benzodiazepines have been employed in drug-facilitated 
sexual assaults; they may produce driving impairment, and even death from overdoses in 
combination with other central nervous system depressants, such as ethanol and opioids (NIH 
National Institute on Drug Abuse, 2019; Vikingsson et al., 2017). In addition to benzodiazepines, 
currently gaining traction for substance abuse are designer benzodiazepines because they are 
easily accessible, can be bought online, are cheap, and most do not fall under the Controlled 
Substance Act, with the exception of clobazam and delorazepam, at the time of publication, so 
they are unmonitored (Moosmann, King, & Auwarter, 2015).  
Designer benzodiazepines, which fall under new psychoactive substances (NPS), such as 
etizolam, diclazepam, flubromazolam, clobazam, and nifoxipam, are even more potent and 
dangerous than regular benzodiazepines, so the same dosage can produce the same or even 
greater effect on the body (Moosmann et al., 2015). For instance, studies show that clonazolam is 
2.5 times more potent than alprazolam with a 20-60 minutes onset of action. Clonazolam causes 
sedation, muscle relaxation, amnesia, respiratory depression, and withdrawals leading to anxiety 
or seizures can occur if the user stops taking it immediately without tapering (Cornett et al., 
2018). For flubromazepam, one of the authors, who self-administered 4 mg of the drug as a 
capsule, felt fatigue and the need to sleep for three days (Moosmann et al., 2013). Because they 






rather self-assess how much of the drug to take. This can often result in unintentional 
overdosing, which can potentially lead to coma or death, especially if combined with other 
depressant substances. 
With the introduction of designer benzodiazepines in the market, there is a lack of 
standardized methods in the toxicology laboratories to screen for the presence of these drugs and 
to confirm these findings in biological samples. Immunochemical tests and enzyme linked 
immunosorbent assays can be used for a preliminary screening; but the target of these screening 
tests are the classic benzodiazepines, and the cross reactivity with the new designer 
benzodiazepines is unknown. Gas chromatography-mass spectrometry (GC-MS) has also been 
used as a screening technique that includes the use of library matches with good sensitivity and 
selectivity, however there can be false negative results for drugs that undergo thermal 
decomposition. In addition, GC-MS analysis is not as sensitive to metabolites and co-eluting 
chromatographic peaks (Guale et al., 2013). Currently, there are several methods described that 
screen a limited number of designer benzodiazepines, including clonazolam, deschloroetizolam, 
flubromazepam, flubromazolam, and meclonazepam, using liquid chromatography time-of-flight 
mass spectrometry (LC-TOF/MS) and liquid chromatography quadrupole time-of-flight mass 
spectrometry (LC-QTOF/MS). However, these methods utilized urine and serum as the matrix of 
analysis and the sample clean-up procedure consisted of liquid-liquid extraction (LLE) or solid 
phase extraction (SPE) (Guale et al., 2013; Huppertz, Bisel, Westphal, & Franz, 2015; 
Moosmann et al., 2013; Pope, Choy, Drummer, & Schneider, 2018; Tomková, Švidrnoch, Maier, 
& Ondra, 2017). 
There are also limited methods available to confirm and quantify the presence of these 






developed to determine the presence of designer benzodiazepines by gas chromatography with 
tandem mass spectrometry (GC-MS/MS) (Nakamae et al., 2008; Meng, Zhu, Zheng, & Fu, 2017) 
and by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in urine or plasma 
as the matrix (Bergstrand, Helander, & Beck, 2016; Oliveira-Silva et al., 2009), but few for ante-
mortem and post-mortem blood and are limited in the number of designer benzodiazepines tested 
(Sauve, Langodegard, Ekeberg, & Oiestad, 2012). Blood is a critical matrix in forensic 
toxicology because blood concentrations can be correlated with impairment. Thus, the purpose of 
the study was to develop and validate a method for the confirmation and quantification of 15 
designer benzodiazepines in blood by LC-MS/MS. 
 
2. Materials and Methods 
2.1. Reagents and Supplies 
3-Hydroxyphenazepam (1 mg/mL in acetonitrile), clobazam (1 mg/mL in methanol), 
clonazolam (1 mg/mL in acetonitrile), delorazepam (100 µg/mL in acetonitrile), 
deschloroetizolam (1 mg/mL in methanol), diclazepam (1 mg/mL in acetonitrile), 
flubromazepam (1 mg/mL in methanol), flubromazolam (1 mg/mL in methanol), meclonazepam 
(1 mg/mL in methanol), nifoxipam (1 mg/mL in 90:10 acetonitrile: dimethyl sulfoxide, v/v), 
pyrazolam (1 mg/mL in acetonitrile), zolazepam (1 mg/mL in methanol), 7-aminoclonazepam-𝑑4 
(1 mg/mL in acetonitrile), diazepam-𝑑5 (1 mg/mL in methanol), chlordiazepoxide-𝑑5 (100 
µg/mL in methanol), nordiazepam-𝑑5 (1 mg/mL in methanol), and temazepam-𝑑5 (1 mg/mL in 
methanol) were purchased from Cerilliant (Round Rock, TX). Flualprazolam and flunitrazolam 
were purchased as powder from Cayman Chemicals (Ann Arbor, MI). 4-chlorodiazepam was 






hydroxide were purchased from Sigma-Aldrich (St. Louis, MO). LCMS grade acetonitrile, 
formic acid, and deionized water were purchased from Spectrum (New Brunswick, NJ). 
Drug-free (negative) calf blood was obtained from Ottomanelli Bros. (New York, NY) 
for the preparation of calibrators and quality control (QC) samples. Postmortem blood samples 
obtained from the New York City Office of Chief Medical Examiner (NYC-OCME) were from 
expired cases previously tested for the presence of common prescription benzodiazepines and a 
limited number of designer benzodiazepines (desalkylflurazepam, etizolam, nimetazepam, and 
phenazepam) were used to determine matrix effects. 
Preconditioned Clean Screen XCEL I SPE columns (130 mg/6 mL) were purchased from 
United Chemical Technologies (Levittown, PA). The SPE columns were mounted on a SPEware 
CEREX® System 48 Processor positive pressure manifold (Tecan, Männedorf, Switzerland). 
 
2.2. Preparation of Calibrators and QCs 
Prior to preparing a working solution, the powders of 4-chlorodiazepam, flualprazolam, 
and flunitrazolam were individually dissolved in methanol to a final concentration of 1 mg/mL. 
Then, a working solution of a mixture of all fifteen designer benzodiazepines was prepared in 
methanol at 10 mg/L. Additional working solutions at 1 mg/L and 0.1 mg/L were prepared 
through serial dilution of the 10 mg/L working solution in methanol. Two sets of working 
solutions were prepared, one for calibrators and one for QC samples. A working standard of a 
mixture all five internal standards (IS) was prepared at a concentration of 1 mg/L in methanol. 







Calibration standards were prepared by adding the appropriate volumes of the working 
solutions of analytes to 0.5 mL negative calf blood, that was aliquoted into labeled 16 x 125 mm 
glass culture tubes, to final concentrations of 1, 5, 10, 50, 100, 200, and 500 ng/mL. QC samples 
were prepared using the same method as the calibrators to final concentrations of 3, 40, 80, and 
300 ng/mL. The volumes of the appropriate stock solution for each desired concentration is 
shown below in Table 1. 
 
Table 1. Guidelines for the Spiking of Calibrators and quality control (QC) Samples 
Sample Type Final Concentration 
(ng/mL) 
Stock Solution of 
Calibrator or QC (mg/L) 
Volume Added 
(µL) 
Calibrator 1 0.1 5 
5 0.1 25 
10 0.1 50 
50 1 25 
100 1 50 
200 10 10 
500 10 25 
QC 3 0.1 15 
40 1 20 
80 1 40 








To 0.5 mL aliquots of all the blood samples, including calibrators, QC samples, and case 
sample blood, 50 µL of the IS working solution (1 mg/L) was added, resulting in a final 
concentration of 100 ng/mL, and vortexed using the Scientific Industries Vortex Genie Z 
(Scientific Industries Inc, Bohemia, NY). One mL of acetate buffer (pH 4.5) was added to each 
tube and mixed by vortexing for 30 s. The tubes were centrifuged at 3,000 rpm for 10 min using 
the Beckman Coulter Allegra X-15R Centrifuge (Beckman Coulter, Brea, CA). The centrifuged 
samples were decanted onto the SPE cartridges with applied pressure at 1-2 psi. After, the 
column was washed with 3 mL of distilled water and 3 mL of 5% acetonitrile in acetate buffer 
(pH 4.5) with applied pressure at 2-4 psi. The columns were dried for 15 min at 60 psi. The 
analytes were eluted with 2 mL of ethyl acetate: ammonium hydroxide (98:2, v/v). Lastly, the 
eluate was evaporated to dryness under nitrogen at 40℃ with the SPEware CEREX® 48 
Concentrator (Tecan, Männedorf, Switzerland), reconstituted with 0.1 mL of the initial mobile 
phase, vortexed for 3 s, centrifuged at 3,000 rpm for 10 min and transferred to sample vials with 
polymer feet for LC-MS/MS analysis.  
 
2.4.Instrumental Parameters 
Two Agilent 1200 Infinity Series LC Systems equipped with an autosampler combined 
with an Agilent 6460 Triple Quadrupole mass spectrometer (Agilent Technologies, Santa Clara, 
CA) were used for the duration of the analysis. An Agilent InfinityLab Poroshell 120 EC18 
column (3.0 mm x 50 mm, 2.7 μm particle size) held at a temperature of 55°C in the column 
compartment was used for chromatographic separations. The mobile phase consisted of 0.1% 






0.7 mL/min. The starting gradient conditions were 15% B, which increased to 20% B over 1.5 
min, then increased to 32% B by 10 min, and lastly ramped to 100% B by 10 min, holding it for 
2 min. The system was then equilibrated back to initial conditions for 1.5 min, with a total run 
time of 13.5 min. The mass spectrometer (MS) analyzed the compounds using Agilent jet 
stream-electrospray ionization (AJS-ESI) under positive mode and data were collected using 
multiple reaction monitoring (MRM). The MS parameters included a gas temperature of 300°C, 
gas flow at 6 L/min, nebulizer at 40 psi, and capillary voltage at 4 kV. All data was recorded and 
processed using Agilent MassHunter Quantitative Analysis for QQQ (B.07.01 SP2). The MS 
parameters for each compound was determined using the Agilent MassHunter Optimizer 
program. The two most abundant product ions of MRM transitions were chosen for each analyte, 
the first for quantitation and the second for ion ratio comparison as confirmation as shown in 
Table 2. 
 
Table 2. MRM Parameters for the 15 Designer Benzodiazepines and 5 internal standards. The 
quantifier ions are the transitions highlighted in bold. 























































































































































2.5. Method Validation 
The method was validated according to the Scientific Working Group for Forensic 
Toxicology (SWGTOX) guidelines (Scientific Working Group for Forensic Toxicology, 2013), 
so that the method can be applied to casework. The parameters analyzed were calibration model, 
bias, intra and inter-day precision, limit of quantitation (LOQ)/ limit of detection (LOD), carry 
over, interferences, matrix effects, dilution integrity, and stability.  
 
2.5.1. Calibration Curve Linearity 
The calibration model was explored over a range of 1-500 ng/mL by fortifying drug-free 
calf blood samples with the working solutions and IS (1 mg/L), extracting, and analyzing as 
described above. The calibration curves were obtained by plotting the ratio of the peak area 
of the analyte to that of the IS versus the concentration. The linear range of each compound 
was determined by running all seven concentrations in five replications, in which each 








2.5.2. Limit of Detection (LOD) and Quantification (LOQ) 
The LOD was considered to be the lowest concentration at which the analyte response 
could be differentiated from that of background noise and had a signal-to-noise ratio (S/N) 
≥3.  The LOQ was the lowest calibrator concentration on the curve and was monitored by 
analyzing nine replicate samples, three replicates over three separate days, for bias and 
precision values (within-run and between-run) to be within 20%.  
 
2.5.3. Bias and Precision 
Bias and precision were evaluated by analyzing the QC samples at 3, 40, 80, and 300 
ng/mL in triplicate over the course of five different days. For each compound, three of the 
four concentrations were chosen for low, medium, and high QC depending on the linear 
range. The acceptable bias range was within ± 20% of each concentration. Precision was 
assessed using the analysis of variance (ANOVA) approach for the coefficient of variance 
(%CV) of within-run and between-run values, which should not exceed 20% for each QC 
level. 
 
2.5.4. Matrix effect and extraction efficiency 
To evaluate the matrix effect, three sets of samples (set 1, set 2, set 3) were prepared by 
fortifying working solutions of the designer benzodiazepines and IS into thirteen sources of 
negative blood distributed amongst the samples, which consisted of calf blood (1), 
postmortem blood (11), and decomposed samples (1). Set 1 contained neat samples of low 






different sources of blood each fortified with both low and high QC and extracted as normal, 
totaling to ten samples. Set 3 consisted of ten different sources of blood which were extracted 
and then fortified with low and high QC after elution, totaling twenty samples. A comparison 
of set 1 to set 3 was used to calculate matrix effects, a comparison of set 2 to set 3 was used 
to demonstrate extraction efficiency. Ion suppression and enhancement were analyzed to 
determine if each analyte in question is influenced by various matrices in the same manner to 
ensure that quantification of that analyte is not affected, therefore the relative standard 
deviation (%RSD) of matrix effect values should be within 20%. 
 
2.5.5. Carryover 
Carryover studies were determined by injecting a negative sample after a sample with 
concentrations at 200, 500, and 1000 ng/mL each in triplicate. Carryover is not present if the 
negative samples do not exhibit a signal greater than that of the LOD.  
 
2.5.6. Interferences 
Interference studies were conducted by fortifying a low QC (3 ng/mL) in triplicate with 
other common drugs of abuse at high concentrations - methadone at 1,000 ng/mL, 
amphetamines, other opioids, and common prescription benzodiazepines at 500 ng/mL, and 
synthetic opioids at 100 ng/mL. If the QC sample calculates within 20% of the expected 
value, then it can be said that the other drugs did not interfere with the analysis. Endogenous 
interference studies were also performed by preparing samples in negative calf blood with 








2.5.7. Dilution Integrity 
Dilution integrity was explored by performing a 1:2 dilution of a 200 ng/mL fortified 
sample and a 1:5 dilution of a 500 ng/mL fortified sample both in calf blood. The original 
samples were diluted in triplicate with blank blood, and the compounds must quantify within 
20% of the target values when multiplied by their respective dilution factors. 
 
2.5.8. Stability 
Stability of the analytes was experimented by re-injecting the QC samples after 24 and 48 
h on the autosampler, which was kept at room temperature. Stability was evaluated by 
comparing the percent difference of the concentration values of fresh samples versus the re-
injected sample, which should stay within 20%.  
 
2.6. Identification and Quantification Criteria 
 The identification criteria for the presence of an analyte was that the peak indicated for 
the compound had a retention time ± 0.2 min window of the average retention times from the 
calibrators, both the quantifier and qualifier ions were both present, and that the ion ratio was 
within ± 20% of the average ion ratio of the calibrators. The quantification criteria for an analyte 
is that the calibration curve must contain at least five of the seven points and that the 𝑅2﹥0.99. In 
addition, if points on the curve were disabled, then the QC samples within the linear range had to 









2.7. Authentic Sample Analysis 
The NYC-OCME toxicology department provided 33 postmortem blood samples 
consisting of either femoral or heart blood, which were collected in blood bottles and vacutainer 
glass collection tubes from 2016 to 2018 and stored in the freezer at -25°C. These specific 
samples were chosen because during routine analysis, which consisted of an initial screening by 
immunoassay and targeted analysis using GC-MS or LC-MS/MS, etizolam and delorazepam 
were detected. Both of these compounds are non-traditional benzodiazepines and therefore could 
potentiate use of other benzodiazepines and benzodiazepine analogs. Prior to analysis, the 
samples were removed from the freezer and were left in the refrigerator at 4°C overnight to 
defrost before aliquoting into 16 x 125 mm glass culture tubes for SPE extraction and LC-




 The LC-MS/MS method applied for the analysis of the panel of designer benzodiazepines   
had excellent sensitivity and selectivity with the ability to detect all the compounds of interest 
within the linear range of 1-500 ng/mL. The chromatographic separation, in which each 
compound was able to be detected, is shown in the total ion chromatogram (TIC) of a low QC 







Figure 1. Total ion chromatogram (TIC) of a low QC sample at 3 ng/mL. The order of elution 
shown in the TIC of all the analytes and internal standards was as follows: zolazepam, 7-
aminoclonazepam-𝑑4, chlordiazepoxide-𝑑5, pyrazolam, nifoxipam, flunitrazolam, clonazolam, 
deschloroetizolam, nordiazepam-𝑑5, flualprazolam, 3-hydroxyphenazepam, flubromazolam, 
temazepam-𝑑5, flubromazepam, meclonazepam, clobazam, delorazepam, diazepam-𝑑5, 
diclazepam, and 4-chlorodiazepam. Note that the additional internal standards were included in 
the working solution, but were not used for this method. See Appendix B for an extracted ion 
chromatogram for each analyte. 
 
3.2. Method Validation 
 The method was validated for the quantification of 13 of the 15 designer benzodiazepines 
in blood from the panel. The 13 designer benzodiazepines consisted of 3-hydroxyphenazepam, 
clobazam, clonazolam, delorazepam, deschloroetizolam, diclazepam, flualprazolam, 






chlorodiazepam and zolazepam were monitored for qualitative analysis only. The results for the 
method validation are summarized in each section below. 
 
3.2.1. Linearity 
The internal standards used for each standard is shown in Table 3 based on the proximity 
of the retention times. The calibration models were linear over a concentration range of 1-
200 ng/mL, except for 3-hydroxyphenazepam, clobazam, flubromazepam, and pyrazolam, 
which had a concentration range of 1-500 ng/mL. All compounds had a line of best fit 
following a linear regression with a 1/𝑥2weighting for all compounds, except 3-
hydroxyphenazepam and flubromazolam, which followed a 1/x weighting, and had an 𝑅2﹥
0.99, which is shown in Table 4.  
 
Table 3. Summary of the internal standards used for each compound and their retention times 
Compound Name Retention 
Time (min) 
Internal Standard Retention 
Time (min) 
3-hydroxyphenazepam 7.9 Temazepam-𝑑5 8.6 
4-chlorodiazepam 11.1 Diazepam-𝑑5 9.1 
Clobazam 9.1 Diazepam-𝑑5 9.1 
Clonazolam 6.3 Nordiazepam-𝑑5 6.0 
Delorazepam 9.3 Diazepam-𝑑5 9.1 
Deschloroetizolam 6.23 Nordiazepam-𝑑5 6.0 
Diclazepam 11 Diazepam-𝑑5 9.1 
Flualprazolam 7.4 Temazepam-𝑑5 8.6 






Flubromazolam 8 Temazepam-𝑑5 8.6 
Flunitrazolam 5.2 Nordiazepam-𝑑5 6.0 
Meclonazepam 9 Diazepam-𝑑5 9.1 
Nifoxipam 4.2 Diazepam-𝑑5 9.1 
Pyrazolam 3.4 Chlordiazepoxide-𝑑5 2.5 
Zolazepam 0.90 7-aminoclonazepam-𝑑4 0.95 
 
 
Table 4. Summary of the linearity ranges, weighting, average 𝑅2 values, CV% of 𝑅2 values, 
average slope values, and CV% of the slope values of each compound (n = 15) 











3-hydroxyphenazepam 1-500 1/x 0.9986 0.098 0.1199 9.146 
Clobazam 1-500 1/𝑥2 0.9949 0.307 1.9193 11.342 
Clonazolam 1-200 1/𝑥2 0.9924 0.557 2.8223 18.298 
Delorazepam 1-200 1/𝑥2 0.9965 0.174 0.2961 5.553 
Deschloroetizolam 1-200 1/𝑥2 0.9962 0.303 6.5509 8.624 
Diclazepam 1-200 1/𝑥2 0.9957 0.211 0.2746 19.567 
Flualprazolam 1-200 1/𝑥2 0.9947 0.174 0.7196 15.615 
Flubromazepam 1-500 1/𝑥2 0.9962 0.178 0.1409 11.970 
Flubromazolam 1-200 1/x 0.9971 0.198 0.3514 5.884 
Flunitrazolam 1-200 1/𝑥 0.9978 0.209 5.0754 6.585 
Meclonazepam 1-200 1/𝑥2 0.9960 0.170 0.5974 8.043 
Nifoxipam 1-200 1/𝑥2 0.9935 0.203 0.0691 11.397 







3.2.2. LOQ and LOD 
The determined LOQ for all analytes was 1 ng/mL where the % bias of the compounds 
were within  ± 20% of the expected value. The intra- and inter-day imprecision % CV also 
did not exceed 20% except for diclazepam and pyrazolam, which were slightly greater. The 
results for bias and imprecision are summarized in Table 5 below. The predetermined LOD 
criteria were met for 0.5 ng/mL where the samples run in triplicate had a signal to noise ratio 
greater than 3. 
 
Table 5. Summary of bias, intra- and inter-day precision results for the LOQ (1 ng/mL) of 
each analyte (n = 9) 
Compound Name Bias (%) Imprecision CV (%) 
Intra-day Inter-day 
3-hydroxyphenazepam -5.78 7.49 9.90 
Clobazam 12.00 6.44 6.25 
Clonazolam 7.78 14.70 12.33 
Delorazepam 6.33 7.61 8.01 
Deschloroetizolam 10.78 11.41 12.87 
Diclazepam 8.89 20.87 21.74 
Flualprazolam 14.22 10.70 9.75 
Flubromazepam -19.78 9.37 10.59 
Flubromazolam -2.67 11.92 15.98 
Flunitrazolam 15.89 13.47 11.09 
Meclonazepam 0.78 6.62 18.18 
Nifoxipam -0.11 8.04 15.03 






3.2.3. Bias and Precision 
The accuracy of the 15 replicates of all compounds were monitored at the low QC (3 
ng/mL), mid QC (40 ng/mL), and high QC (80 ng/mL), except for 3-hydroxyphenazepam, 
clobazam, and flubromazepam, which have a mid QC at 80 ng/mL and high QC at 300 
ng/mL due to their expanded calibration ranges. The calculated mean and bias results were 
within acceptable ranges of ± 15% the expected value as shown in Table 6 below. 
Table 6. Summary of bias results for low, mid, and high QC for each compound (n = 15) 
Compound Name Bias (%) 
Low QC Mid QC High QC 
3-hydroxyphenazepam 
QC = 3, 80, 300 ng/mL 
-9.58 -7.03 -0.82 
Clobazam 
QC = 3, 80, 300 ng/mL 
-11.76 -6.40 3.64 
Clonazolam 
QC = 3, 40, 80 ng/mL 
11.60 10.34 -0.76 
Delorazepam 
QC = 3, 40, 80 ng/mL 
7.22 8.51 5.76 
Deschloroetizolam 
QC = 3, 40, 80 ng/mL 
1.13 4.92 2.47 
Diclazepam 
QC = 3, 40, 80 ng/mL 
4.02 2.81 -5.83 
Flualprazolam 
QC = 3, 40, 80 ng/mL 
2.71 1.38 -5.40 
Flubromazepam 
QC = 3, 80, 300 ng/mL 
-10.64 -10.53 -7.95 
Flubromazolam 
QC = 3, 40, 80 ng/mL 
-3.02 1.11 -4.02 
Flunitrazolam 
QC = 3, 40, 80 ng/mL 
1.20 2.99 3.53 
Meclonazepam 
QC = 3, 40, 80 ng/mL 
3.64 5.29 2.06 
Nifoxipam 
QC = 3, 40, 80 ng/mL 
-6.58 1.81 3.60 
Pyrazolam 
QC = 3, 40, 80 ng/mL 







All intra-day imprecision CV results were within 20% as shown below in Table 7 and all 
inter-day imprecision CV results were within 20%, except for diclazepam at mid QC, which 
was slightly above. 
 
Table 7. Summary of intra- and inter-day precision results at low, mid, and high QC for each 
compound (n = 15) 
Compound Name Low QC 
Imprecision CV (%) 
Mid QC 
Imprecision CV (%) 
High QC 
Imprecision CV (%) 
Intra-day Inter-day Intra-day Inter-day Intra-day Inter-day 
3-hydroxyphenazepam 
QC = 3, 80, 300 ng/mL 
4.70 4.67 5.95 8.31 5.14 6.99 
Clobazam 
QC = 3, 80, 300 ng/mL 
3.68 5.06 7.74 7.93 5.27 7.12 
Clonazolam 
QC = 3, 40, 80 ng/mL 
6.02 8.88 7.37 11.43 4.65 6.44 
Delorazepam 
QC = 3, 40, 80 ng/mL 
3.77 4.99 6.03 6.36 5.48 6.30 
Deschloroetizolam 
QC = 3, 40, 80 ng/mL 
7.26 9.82 8.06 12.29 5.66 8.17 
Diclazepam 
QC = 3, 40, 80 ng/mL 
12.24 13.38 19.11 20.58 8.92 11.97 
Flualprazolam 
QC = 3, 40, 80 ng/mL 
15.41 16.16 9.03 8.68 9.10 10.04 
Flubromazepam 
QC = 3, 80, 300 ng/mL 
7.16 11.35 8.15 8.92 12.99 12.47 
Flubromazolam 
QC = 3, 40, 80 ng/mL 
9.06 10.16 10.73 9.88 8.37 8.331 
Flunitrazolam 
QC = 3, 40, 80 ng/mL 
6.07 8.64 8.81 10.39 6.39 7.55 
Meclonazepam 
QC = 3, 40, 80 ng/mL 
4.95 6.15 5.41 6.97 6.89 7.09 
Nifoxipam 
QC = 3, 40, 80 ng/mL 
6.27 7.54 6.46 7.21 6.67 6.25 
Pyrazolam 
QC = 3, 40, 80 ng/mL 









3.2.4. Matrix effect and extraction efficiency 
Matrix effect will cause either ion suppression, seen as negative values, or enhancement, 
which is seen as positive values. It can be said that a compound is not significantly 
susceptible to matrix effect if the value is within ± 25% of the expected value. Should an 
analyte have significant matrix effect, then it has to be proven that the matrix effect does not 
inhibit the analysis. Matrix effect is within the ± 25% acceptable range for all compounds, 
except delorazepam at high concentrations, deschloroetizolam at low concentrations, 
diclazepam at both high and low concentrations, and flubromazepam at low concentrations, 
as shown in Table 8. It is shown that %RSD is within 20% indicating that the analyte exhibits 
the same behavior in each matrix and is repeatable for testing conditions, so matrix effect is 
not a concern in the quantification of the analytes.  
 
Table 8. Summary of matrix effect results for each compound at low QC (3 ng/mL) and high QC 
(300 ng/mL) in blood samples (n = 10) 
Compound Name Low QC 3 ng/mL High QC 300 ng/mL 
Matrix Effect (%) RSD (%) Matrix Effect 
(%) 
RSD (%) 
3-hydroxyphenazepam 2.1 5.2 3.3 4.6 
4-chlorodiazepam -79.4 22.7 -66.9 19.0 
Clobazam 17.4 19.8 0.9 4.7 
Clonazolam -10.5 4.9 13.6 4.3 
Delorazepam -5.2 7.7 -52.1 4.8 
Deschloroetizolam -29.6 11.4 -12.1 3.2 
Diclazepam -41.9 17.3 -39.5 16.4 
Flualprazolam 7.8 17.0 4.2 8.0 






Flubromazolam -1.8 12.9 1.8 7.3 
Flunitrazolam -3.0 8.0 -1.9 4.4 
Meclonazepam -7.9 6.7 -5.8 3.9 
Nifoxipam 8.9 9.5 2.0 8.5 
Pyrazolam -15.6 9.5 -4.9 7.1 
Zolazepam -33.8 11.7 -21.2 6.6 
7-aminoclonazepam-𝑑4 5.4 3.4 -14.4 12.2 
Chlordiazepoxide-𝑑5 -12.2 5.1 -6.7 4.2 
Diazepam-𝑑5 -8.5 4.6 -7.5 3.2 
Nordiazepam-𝑑5 2.2 6.5 -5.0 3.8 
Temazepam-𝑑5 -6.0 4.5 -0.1 5.5 
 
Extraction efficiency was evaluated for all the compounds, which ranged from 35.4-
83.9%. Nifoxipam had low recovery at 37.3% for low QC (3 ng/mL) and 35.4% for high QC 
(300 ng/mL) and 3-hydroxyphenazepam also had a slightly low recovery at 49.6% at low QC 
and 49.0% at high QC, but all other compounds had extraction efficiencies greater than 50%, 
which is the optimal extraction efficiency. Despite the values below the optimal extraction 
efficiency, the other validation parameters were not affected and met the acceptability 
criteria, so it can be said that the low extraction efficiency did not compromise the analysis. 
 
3.2.5. Carryover 
Carryover was not present in any of the blank matrix samples injected after the 
concentrations of 200, 500, and 1,000 ng/mL in triplicate. None of the blank matrix samples 








The present studies showed that endogenous compounds did not cause interference in 
specificity and selectivity of the analysis. The identification of the target analytes was not 
influenced by exogenous compounds; however, there was potential interference for the 
quantitation of delorazepam, diclazepam, flubromazepam, flunitrazolam, and pyrazolam. 
Delorazepam, diclazepam, and pyrazolam had accuracies greater than 120% and 
flubromazepam and flunitrazolam had accuracies less than 80% of the low QC (3 ng/mL). It 
is uncertain as to the source of interference for delorazepam and diclazepam, but additional 
studies will be performed to confirm as to which of the commonly abused drugs are causing 
the interference. All other compounds quantitated within ± 20% of the low QC. 
 
3.2.7. Dilution Integrity 
Drug-free calf blood was used to test a 1:2 dilution of a prepared 200 ng/mL sample and 
a 1:5 dilution of a 500 ng/mL sample with both concentrations analyzed in triplicate. The 
concentrations of the repeats for diclazepam in the 1:5 dilution and nifoxipam in the 
1:2 dilution did not quantitate within 20% of the expected concentration. Diclazepam 
quantitated -40.2% of the expected value and nifoxipam quantitated 52.5% above the 
expected value. The other analytes calculated within the ± 20% range for one or more repeat 
for both the 1:2 and 1:5 dilution. 
 
3.2.8. Stability 
Extracted samples at low and high QC were re-injected after 24 and 48 h on the 






showed deterioration at high QC of -25.7% and flubromazepam at low and high QC of -
56.6% and -52.5%, respectively, after 24 h. Clonazolam, deschloroetizolam, diclazepam, 
flualprazolam,  and flunitrazolam had a percent difference either at or greater than 25% after 
24 h compared to the original sample. Clonazolam at low and high QC had a difference of 
55.6% and 72.4%, respectively. Deschloroetizolam at low and high QC had a difference of 
55.1% and 57.4%, respectively. Diclazepam had a difference of 66.1% at low QC and 31.8% 
at high QC. Flualprazolam had a difference of 25% at low QC after 24 h and a difference of 
36.4% at high QC after 48 h. Flunitrazolam at low and high QC had a difference of 51.7% 
and 50.1%, respectively. 3-hydroxyphenazepam at low and high QC and flubromazolam at 
high QC had a percent difference exceeding 25% after 48 h on the autosampler, which were 
32.4%, 34.5%, and 29.4%, respectively. All other analytes had results within the acceptable 
range between fresh samples and samples on the autosampler after the allotted time.  
 
3.3. Authentic Case Samples 
Postmortem blood samples were subjected to the conditions of the aforementioned 
method. Of the thirty-three samples that were re-analyzed, five of the samples tested positive for 
additional designer benzodiazepines, including clonazolam, delorazepam, diclazepam, 
flualprazolam, and flubromazolam. The drugs found along with their concentrations in each case, 
and the original test results are summarized in Table 9 and a comparison of the peak signal of 









Table 9. Additional Designer Benzodiazepines Identified in Postmortem Blood Samples 
Originally Tested between 2016 to 2018 
Case and Source Original Test Results Additional Drugs Identified 
1 (Heart) Lorazepam – 13 ng/mL (GC-MS) 
Etizolam – detected (GC-MS) 
Delorazepam – 68.91 ng/mL 
Diclazepam – 0.93 ng/mL 
Flubromazolam – 40.37 ng/mL 
2 (Femoral) Etizolam – detected (GC-MS) Delorazepam – 1.13 ng/mL 
3 (Femoral) Diazepam – 458 ng/mL (LC-MS/MS) 
Nordiazepam – 1,106 ng/mL (LC-
MS/MS) 
Etizolam – 56 ng/mL (LC-MS/MS) 
Lorazepam – 12 ng/mL (LC-MS/MS) 
Oxazepam – 29 ng/mL (LC-MS/MS) 
Temazepam – 38 ng/mL (LC-MS/MS) 
Delorazepam – 68.69 ng/mL 
4 (Femoral) 7-aminoclonazepam – 1.3 ng/mL (LC-
MS/MS) 
Etizolam – 15 ng/mL (LC-MS/MS) 
Clonazolam – 1.16 ng/mL 
5 (Femoral) Alprazolam – 171 ng/mL (LC-MS/MS) 
Alphahydroxyalprazolam – 5.1 ng/mL 
(LC-MS/MS) 
Lorazepam – 1.4 ng/mL (LC-MS/MS) 
Delorazepam – 5.38 ng/mL 














Figure 2. Comparison of peak signal and ion ratios of clonazolam in authentic case 4 (top) to the 
LOQ at 1 ng/mL (bottom) 
 
4. Discussion 
The quantification method for designer benzodiazepines in blood was validated for 13 of 
the 15 compounds, while 4-chlorodiazepam and zolazepam were monitored for qualitative 
analysis only. All method validation criteria was explored and tested to see if the necessary 
standards were met. The LOQ was set at 1 ng/mL and the LOD was 0.5 ng/mL (S/N >3). Bias 
and precision CV% quantitated within the required 20% with the exception of diclazepam at mid 
QC (40 ng/mL) for inter-day imprecision, which was just barely above. Although there was 
matrix effect and low extraction efficiencies for a few of the compounds, the other method 
validation parameters were not affected and is not considered a concern for the quantification of 
the 13 analytes. Carryover was not present in samples as high as 1,000 ng/mL as seen in the 






expected concentration with the exception of diclazepam in the 1:5 dilution and nifoxipam in the 
1:2 dilution.  
There were some issues regarding interference studies and stability of the compounds. It 
was observed that there were no endogenous interferences and that the majority of the target 
analytes were not affected by exogenous compounds. However, it has been reported that 
chlordiazepoxide and midazolam interfere with flubromazepam analysis, while oxazepam 
interferes with pyrazolam (NMS Labs, 2018). Because flunitrazolam shares a highly similar 
structure to flubromazepam, chlordiazepoxide and midazolam are also potential interferences to 
this compound. 
There is limited published data regarding the stability of designer benzodiazepines, but 
the drugs share similar properties with classic benzodiazepines, since the designer drugs are 
derivatives of the 1, 4-benzodiazepine structure. Previous studies show that benzodiazepines in 
general are not stable with a few exceptions, such as diazepam. A compound is also said to be 
more stable if it is a metabolite, rather than a parent compound (Uddin, Samanidou, & 
Papadoyannis, 2010; Dixon, Mbeunkui, & Wiegel, 2015; Gautam, Sharratt, & Cole, 2014). 
Benzodiazepines are more unstable if stored in positive temperatures, which was tested in a 
study where benzodiazepines stored at room temperatures were extracted and analyzed after set 
amounts of time. After a year, the quantitated value of the low concentration samples decreased 
by 100% (Gautam, Sharratt, & Cole, 2014; Mahjoub & Staub, 2000). Another study tested the 
stability of post extracted benzodiazepines in hair by storing the samples in the autosampler at 
10˚C, showing degradation in some analytes after 48 h up to 54.8% loss (Lendoiro et al., 2012).  
Compared to other methods described, this method simultaneously quantitates 13 






min run time and LC-MS/MS analysis. The LOQ of all the compounds was as low as 1 ng/mL. 
Previous publications have focused on urine as the biological matrix. An ultrasound-assisted 
low-density solvent dispersive liquid-liquid microextraction was employed to determine 4 
designer benzodiazepines in 1 mL of urine using GC-MS/MS that had a total run time of 20 min 
and a linear range of 0.3 to 20,000 ng/mL (Meng et al., 2017). Another method analyzed 11 
designer benzodiazepines in urine using LC-MS/MS by direct injection after enzymatic 
hydrolysis (Bergstrand et al., 2016). In this method 50 µL of urine were employed, achieving an 
LOQ from 1 to 10 ng/mL.  
Two other publications reported analytical methods for the determination of a limited 
number of designer benzodiazepines in blood. One discussed the analysis of etizolam and its two 
metabolites in 1 mL of whole blood by using SPE cleanup with a derivatization step and analysis 
using ion trap GC-MS over a 17 min run time with a linear range of 5-50 ng/mL (Nakamae et al., 
2008). Hoiseth et al. briefly described a quantitation method for 6 designer benzodiazepines 
using liquid-liquid extraction (borate buffer pH 11 and ethyl acetate/heptane, 4:1) followed by 
LC-MS/MS analysis. They achieved LOQs from 0.37 to 3.5 ng/mL, but the required amount of 
blood was not reported (Hoiseth et al., 2016). In comparison to previously published methods, 
the validated method is an alternative for a simultaneous determination of 13 designer 
benzodiazepines using a quick and easy sample preparation that requires a small volume of blood 
sample (0.5 mL), a fast run time on the LC-MS/MS, which is specific and sensitive, and has a 
LOQ as low as 1 ng/mL. In addition, this developed method has been combined with the current 









A reproducible, simple, and specific method was validated for the simultaneous 
determination of 13 designer benzodiazepines in blood. This method utilized a SPE procedure 
and a 13.5 min run time on the LC-MS/MS. Even with the increase in usage of designer 
benzodiazepines as monitored over the last several years, there have been a limited number 
involving LC-MS/MS techniques described in literature. This method provides an alternative 
technique in contrast to those that use urine as the matrix or GC-MS as the instrument of 
analysis. 
 
6. Future Work 
 With the implementation for the quantitation method of designer benzodiazepines on the 
LC-MS/MS, the next step will be the development of a sensitive screening technique by liquid 
chromatography-time of flight mass spectrometer (LC-TOF/MS). Currently being tested is a 
quick dilute-and-shoot method of sample clean-up for a mixture of 35 benzodiazepines and 
designer benzodiazepines and 10 internal standards in blood. The identification criteria in the 
LC-TOF/MS consists on retention time and precursor accurate mass. 
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Appendix A: Acronyms and Abbreviations 
AJS-ESI  Agilent Jet Stream - Electrospray Ionization 
ANOVA  Analysis of Variance 
CV   Coefficient of Variation 
GC-MS  Gas Chromatography-Mass Spectrometry 
GC-MS/MS  Gas Chromatography-Tandem Mass Spectrometry 
IS   Internal Standard 
LC-MS/MS  Liquid Chromatography-Mass Spectrometry 
LC-QTOF/MS Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry 
LC-TOF/MS  Liquid Chromatography Time-of-Flight Mass Spectrometry 
LLE   Liquid-liquid Extraction 
LOD   Limit of Detection 
LOQ   Limit of Quantitation 
MRM   Multiple Reaction Monitoring 
MS   Mass Spectrometry 
NPS   New Psychoactive Substances 
NYC-OCME  New York City Office of Chief Medical Examiner 
QC   Quality Control 
RSD   Relative Standard Deviation 
S/N   Signal to Noise 
SOP   Standard Operating Procedure 






SWGTOX  Scientific Group for Forensic Toxicology 
TIC   Total Ion Chromatogram 
 
 

















































































Figure 3. Extracted ion chromatograms of each analyte at 3 ng/mL. The quantifier transition is 
shown in the peak on the left and the qualifier transition is shown on the right. 
